Jyong Biotech targets urinary disorders with a novel botanical pipeline, but clinical and liquidity risks temper near-term upside. Read why MENS stock is a hold.

Shortly after the U.S. FDA announced an investigation into the death of a patient who had received Elevidys, a gene therapy developed by Sarepta Therapeutics (NASDAQ:SRPT), the company said that the ...

A joint investigation by KFF Health News and NBC News found that cosmetic surgery chains have been the target of scores of ...

It’s now been a few weeks since the One Big Beautiful Bill became law. It seems clear that the new law will make our debt ...

Social media fueled a flavor mix of chocolate, pistachio and kataifi dough—and now big food companies are betting on its staying power.